Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Recommend:
0
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
Recommend :
0
React to this article
Latest news
Date Title
1m ago INTERTEK : New allocation services manager to grow Intertek team
1m ago AMERICAN CAPITAL AGENCY : Announces Change from Quarterly to Monthly Common Dividend Distributions and the Commencement of Monthly Net Asset Value Estimates
1m ago Fitch Affirms Hewlett-Packard's IDR at 'A-'; Outlook Stable
1m ago Fitch Rates MetLife's Debt Issuance 'A-'
2m ago Fitch Assigns Final Ratings to WFRBS Commercial Mortgage Trust 2014-C23 Pass-Thru Certificates
2m agoDJCDC Confirms First Case of Ebola in U.S.
2m ago DT ASIAUT : Asia : Investments Limited Announces Pricing of Initial Public Offering
3m ago COMCAST : Correction
3m ago WHOLE FOODS MARKET : Jacksonville journal
4m ago BARCLAYS BANK OF KENYA : chief gets Africa job
Latest news
Advertisement
Hot News 
Bank derivatives boom ahead of ECB test results as investors play safe
News Corp to buy real estate website operator Move for $950 mln
CYAN : Executive Chairman role and grant of options
EASTERN PROPERTY : announces the acquisition of full ownership of Class A office complex Severnoe Siyanie
RAME ENERGY : Says Widened Loss Is "In Line With Expectations"
Most Read News
16h ago QUINDELL : simply quizzical over its sliding shares
1d ago LENOVO : edges close to IBM server deal
1d ago SOFTBANK : DreamWorks Animation talks cool - WSJ
1h ago Wall St. ends down for day, month; indexes gain in quarter
1d ago ALLERGAN : Valeant Pharmaceuticals' third-quarter sales to rise
Most recommended articles
2m agoDJCDC Confirms First Case of Ebola in U.S.
10m agoDJADR Shares End Lower; America Movil, HSBC Shares Trade Actively
18m agoDJIn Significant Test, Fed Facility Fails to Defend Short-Term Rate Floor
27m ago BANK OF NEW YORK MELLON : BNY Mellon to shut derivatives sales, trading business: Bloomberg
28m agoDJCURRENCIES : Dollar Index Sees Biggest Quarterly Rise Since 2008
Dynamic quotes  
ON
| OFF